Compared to tumor cells with wild-type BRAF, tumor cells with BRAF V600E displayed a greater reduction of ACTH secretion in response to vemurafenib, with an approximate half-maximal inhibitory concentration (IC50) of 0.3 μM, within the range of IC50 values reported for vemurafenib-sensitive tumor cells (Fig. 2f). This evidence concerns the gene POMC and neoplasm.